User:Mr. Ibrahem/Risankizumab

Risankizumab, sold under the brand name Skyrizi, is a medication used to treat moderate to severe plaque psoriasis. Other uses may include generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.

Common side effects include upper respiratory tract infection, headache, tiredness, and pain at the site of injection. It also increases the risk of other infections. While there is no evidence of harm in pregnancy, such use has not been well studied. It is a monoclonal antibody that attaches to and blocks interleukin 23A (IL-23A).

Risankizumab was approved for medical use in the United States in 2019. In the United States it costs about 17,800 USD per dose as of 2021. In the United Kingdom this amount costs the NHS about £3,300.